Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 6
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 6

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderAcadia · 53
Strongest available pathCrinetics · +303.6%
Widest latest marginRigel · 124.7%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ACAD · Nasdaq

Acadia

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1993San Diego, California$4.95B market cap
View full Companies Radar profile
53Moderate
Snapshot price$28.91as of page date
Monthly-close return+74.1%five-year window
FY2025 revenue$1.07BACADIA PHARMACEUTICALS INC
Net margin36.5%FY2025
P/E snapshot13.0xone ratio, not a verdict
Prism attention43.4%share across these five
Filing track recordRevenue, USD billions
+121.3%
$0$0.4B$0.7B$1.1BFY2021: $0.484BFY2022: $0.517BFY2023: $0.726BFY2024: $0.958BFY2025: $1.072B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.0%
52-week position82% through range
$19.69$30.96
News mentions13.0K
Community mentions861partial coverage
U.S.-scope patents645
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position12/100
Capital-event signal49/100
Innovation pulse24/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2CRNX · Nasdaq

Crinetics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2008San Diego, California$9.01B market cap
View full Companies Radar profile
53Moderate
Snapshot price$84.95as of page date
Monthly-close return+303.6%five-year window
FY2025 revenue$0.01BCrinetics Pharmaceuticals, Inc.
Net margin-6046.2%FY2025
P/E snapshot-21.0xone ratio, not a verdict
Prism attention1.9%share across these five
Filing track recordRevenue, USD billions
+217.0%
$0$0.0B$0.0B$0.0BFY2018: $0.002BFY2019: $0.001BFY2020: $0.000BFY2025: $0.008B2018201920202025
FY2018–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 46.9%
52-week position100% through range
$31.00$85.01
News mentions567
Community mentions13partial coverage
U.S.-scope patents402
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position0/100
Capital-event signal72/100
Innovation pulse17/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 9 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3RIGL · Nasdaq

Rigel

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1996San Francisco, California$854.4M market cap
View full Companies Radar profile
53Moderate
Snapshot price$46.18as of page date
Monthly-close return+27.2%five-year window
FY2025 revenue$0.29BRIGEL PHARMACEUTICALS INC
Net margin124.7%FY2025
P/E snapshot2.7xone ratio, not a verdict
Prism attention7.5%share across these five
Filing track recordRevenue, USD billions
+97.2%
$0$0.1B$0.2B$0.3BFY2021: $0.149BFY2022: $0.120BFY2023: $0.117BFY2024: $0.179BFY2025: $0.294B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 18.5%
52-week position78% through range
$24.95$52.24
News mentions2.2K
Community mentions0partial coverage
U.S.-scope patents2431
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal74/100
Management stability90/100
Market position3/100
Capital-event signal75/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4REGN · Nasdaq

Regeneron Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2020Tarrytown, New York$82.27B market cap
View full Companies Radar profile
52Moderate
Snapshot price$799.1as of page date
Monthly-close return+32.0%five-year window
FY2025 revenue$14.34BREGENERON PHARMACEUTICALS, INC.
Net margin31.4%FY2025
P/E snapshot19.8xone ratio, not a verdict
Prism attention42.7%share across these five
Filing track recordRevenue, USD billions
-10.8%
$0$5.4B$10.7B$16.1BFY2021: $16.072BFY2022: $12.173BFY2023: $13.117BFY2024: $14.202BFY2025: $14.343B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -2.8%
52-week position84% through range
$541.0$847.0
News mentions12.8K
Community mentions165partial coverage
U.S.-scope patents49
Prism Insights

What sits behind the readiness signal

Observed risk 13/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position47/100
Capital-event signal55/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 24 M&A involvements, 12 asset-acquisition events and 15 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 3 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5TGTX · Nasdaq

TG Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1993New York City, New York$8.31B market cap
View full Companies Radar profile
52Moderate
Snapshot price$54.30as of page date
Monthly-close return+63.2%five-year window
FY2025 revenue$0.62BTG THERAPEUTICS, INC.
Net margin72.6%FY2025
P/E snapshot19.8xone ratio, not a verdict
Prism attention4.5%share across these five
Filing track recordRevenue, USD billions
+163.8%
$0$0.2B$0.4B$0.6BFY2023: $0.234BFY2024: $0.329BFY2025: $0.616B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 62.4%
52-week position85% through range
$26.76$59.30
News mentions1.4K
Community mentions0partial coverage
U.S.-scope patents88
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal79/100
Management stability90/100
Market position0/100
Capital-event signal49/100
Innovation pulse17/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Crinetics
+303.6%
Acadia
+74.1%
TG Therapeutics
+63.2%
Regeneron Pharmaceuticals
+32.0%
Rigel
+27.2%

Latest revenue

USD billions, official filing scope shown on each company card.

Regeneron Pharmaceuticals
$14.34B
Acadia
$1.07B
TG Therapeutics
$0.62B
Rigel
$0.29B
Crinetics
$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Rigel
124.7%
TG Therapeutics
72.6%
Acadia
36.5%
Regeneron Pharmaceuticals
31.4%
Crinetics
-6046.2%

Prism news attention

Normalized share across these five names; attention is not quality.

Acadia
43.4%
Regeneron Pharmaceuticals
42.7%
Rigel
7.5%
TG Therapeutics
4.5%
Crinetics
1.9%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Acadia leads the conversation

It holds 43.4% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $1.07B.

Price path

Crinetics leads the available price paths

Its monthly-close return is +303.6% for the five-year window. At the other end, Rigel is +27.2% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Rigel has the widest latest margin

Its FY2025 net margin is 124.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Crinetics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -21.0x while its five-year window price return is +303.6%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ACAD

Acadia

12,999available Prism news records

Prism top themes

Price action & investor response
169
Earnings & financial performance
106
Capital allocation & transactions
90
Leadership & governance
78
Legal, arbitration & regulatory
70

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-28.4%1,482 latest 12m vs 2,070 prior 12m
2024-02: 106 mentions2024-03: 148 mentions2024-04: 125 mentions2024-05: 141 mentions2024-06: 91 mentions2024-07: 89 mentions2024-08: 110 mentions2024-09: 196 mentions2024-10: 221 mentions2024-11: 229 mentions2024-12: 138 mentions2025-01: 159 mentions2025-02: 405 mentions2025-03: 127 mentions2025-04: 128 mentions2025-05: 136 mentions2025-06: 101 mentions2025-07: 120 mentions2025-08: 194 mentions2025-09: 175 mentions2025-10: 133 mentions2025-11: 124 mentions2025-12: 116 mentions2026-01: 110 mentions2026-02: 160 mentions2026-03: 126 mentions2026-04: 182 mentions2026-05: 135 mentions2026-06: 25 mentions2026-07: 2 mentions2024-022026-07

Machine-classified coverage tone

75.1% positive+2.0 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

national park 84stock performance 58national park adventures 55wilderness conservation 43hiking trails 41orphan drug pricing 37stock price 36gene therapy rare diseases 32

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-06–2026-07-16 · trend and themes shown through 2026-07
Areas of research · RIGL

Rigel

2,242available Prism news records

Prism top themes

Price action & investor response
90
Capital allocation & transactions
46
Earnings & financial performance
20
Leadership & governance
19
Legal, arbitration & regulatory
19

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-29.8%340 latest 12m vs 484 prior 12m
2024-01: 20 mentions2024-02: 23 mentions2024-03: 19 mentions2024-04: 19 mentions2024-05: 13 mentions2024-06: 12 mentions2024-07: 16 mentions2024-08: 11 mentions2024-09: 11 mentions2024-10: 8 mentions2024-11: 18 mentions2024-12: 12 mentions2025-01: 35 mentions2025-02: 271 mentions2025-03: 35 mentions2025-04: 6 mentions2025-05: 18 mentions2025-06: 43 mentions2025-07: 22 mentions2025-08: 17 mentions2025-09: 30 mentions2025-10: 23 mentions2025-11: 27 mentions2025-12: 25 mentions2026-01: 28 mentions2026-02: 40 mentions2026-03: 26 mentions2026-04: 44 mentions2026-05: 52 mentions2026-06: 6 mentions2024-012026-06

Machine-classified coverage tone

91.8% positive+0.4 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 24angiogenesis inhibitors 19stock performance 13astrometry 11orphan drug pricing 11company valuation 10phase iii trial 9celestial navigation 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-20–2026-06-05 · trend and themes shown through 2026-06
Areas of research · REGN

Regeneron Pharmaceuticals

12,792available Prism news records

Prism top themes

Legal, arbitration & regulatory
231
Price action & investor response
226
Capital allocation & transactions
186
Earnings & financial performance
134
Macro demand & rates
134

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+22.0%1,799 latest 12m vs 1,474 prior 12m
2024-02: 86 mentions2024-03: 98 mentions2024-04: 85 mentions2024-05: 144 mentions2024-06: 89 mentions2024-07: 87 mentions2024-08: 121 mentions2024-09: 119 mentions2024-10: 93 mentions2024-11: 97 mentions2024-12: 83 mentions2025-01: 154 mentions2025-02: 200 mentions2025-03: 117 mentions2025-04: 118 mentions2025-05: 141 mentions2025-06: 141 mentions2025-07: 90 mentions2025-08: 146 mentions2025-09: 126 mentions2025-10: 124 mentions2025-11: 120 mentions2025-12: 90 mentions2026-01: 128 mentions2026-02: 399 mentions2026-03: 137 mentions2026-04: 309 mentions2026-05: 179 mentions2026-06: 40 mentions2026-07: 1 mentions2024-022026-07

Machine-classified coverage tone

78.6% positive+5.3 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 157generic drug approval 101copyright assignment 99copyright fair use 99copyright enforcement 99copyright remedies 99copyright duration 99brand protection programs 95

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-07-09 · trend and themes shown through 2026-07
Areas of research · TGTX

TG Therapeutics

1,360available Prism news records

Prism top themes

Price action & investor response
104
Earnings & financial performance
38
Capital allocation & transactions
35
Legal, arbitration & regulatory
27
Macro demand & rates
2

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-3.5%191 latest 12m vs 198 prior 12m
2024-01: 30 mentions2024-02: 21 mentions2024-03: 19 mentions2024-04: 14 mentions2024-05: 18 mentions2024-06: 19 mentions2024-07: 2 mentions2024-08: 24 mentions2024-09: 13 mentions2024-10: 5 mentions2024-11: 38 mentions2024-12: 7 mentions2025-01: 12 mentions2025-02: 22 mentions2025-03: 34 mentions2025-04: 21 mentions2025-05: 14 mentions2025-06: 6 mentions2025-07: 4 mentions2025-08: 14 mentions2025-09: 27 mentions2025-10: 13 mentions2025-11: 16 mentions2025-12: 4 mentions2026-01: 23 mentions2026-02: 30 mentions2026-03: 13 mentions2026-04: 20 mentions2026-05: 19 mentions2026-06: 8 mentions2024-012026-06

Machine-classified coverage tone

100.0% positive+3.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 17t-cell lymphoma 15checkpoint inhibitors lymphoma 12earnings report 12antibody-drug conjugates lymphoma 11stock performance 11phase iii trial 10ms disease-modifying therapies 10

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-12–2026-06-19 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

ACAD

Acadia

861 mentions
Stock and valuation
105
Products, pricing and logistics
24
Workplace and hiring
7

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 861 records remained after filtering.

REGN

Regeneron Pharmaceuticals

165 mentions
Stock and valuation
72
Products, pricing and logistics
13
Workplace and hiring
9

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 165 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ACAD

Acadia

through 2026-03-03
Company announcements 33Leadership changes 29Earnings releases 19Listing / IPO 9Regulatory 4
  1. Leadership changes

    Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026.

  2. Earnings releases

    GAAP total revenues were $284 million for the fourth quarter of 2025.

  3. Company announcements

    Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 4, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 161,676 shares of common stock and 49,363 restricted stock units (“RSUs”) to eighteen new employees under Acadia’s 2024 Inducement Plan.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CRNX

Crinetics

through 2026-02-26
Company announcements 55Earnings releases 16Leadership changes 3Listing / IPO 3
  1. Earnings releases

    Revenue was $6.2 million and $7.7 million for the quarter and year ended December 31, 2025, compared to $0

  2. Company announcements

    Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,575 shares of its common stock and granted an aggregate of 25,525 restricted stock unit (“RSU”) awards to 10 new non-executive employees...

  3. Leadership changes

    Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Tobin “Toby” Schilke as chief financial officer, effective February 28, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RIGL

Rigel

through 2026-04-28
Earnings releases 31Listing / IPO 9Leadership changes 3Regulatory 3Company announcements 2
  1. Earnings releases

    Rigel Pharmaceuticals, Inc. today announced that it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026.

  2. Leadership changes

    Rigel Pharmaceuticals appointed Michael P. Miller to the board of directors.

  3. Regulatory

    Rigel Pharmaceuticals Inc.’s ahead-of-deadline approval from the U.S. FDA of Rezlidhia (olutasidenib) twice-daily capsules for adults with relapsed/refractory (r/r) acute myeloid leukemia (AML) came as a surprise to the company

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

REGN

Regeneron Pharmaceuticals

through 2026-04-30
Earnings releases 49Lawsuits 32Leadership changes 18Asset acquisitions 12Company announcements 12
  1. Earnings releases

    Regeneron Pharmaceuticals has reported GAAP net income of $727m for the first quarter of 2026 (Q1 2026), down 10% from $809m in Q1 2025.

  2. M&A

    Invesco Ltd. grew its position in Regeneron Pharmaceuticals by 38.0% in the third quarter.

  3. Business contracts

    On Monday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced a deal with Melbourne-based Telix Pharmaceuticals Ltd. (ASX:TLX; NASDAQ:TLX) to co-develop and co-commercialize four programs, with options to add four more.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TGTX

TG Therapeutics

through 2026-03-02
Earnings releases 52Company announcements 9Business contracts 4Regulatory 1
  1. Earnings releases

    Net income for Q4 was $23 million, or $0.14 per diluted share.

  2. Company announcements

    TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business outlook for the remainder of 2025.

  3. Business contracts

    TG Therapeutics, Inc. (NASDAQ: TGTX) has committed to a multi-year manufacturing supply agreement for BRIUMVI® (ublitiximab-xiiy)

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 26–33. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Crinetics has the widest attention-readiness rank gap

It ranks #5 by measured news attention (1.9%) and #2 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Crinetics in Companies Radar

Regeneron Pharmaceuticals shows a price-operating divergence to inspect

Its displayed filing-revenue change is -10.8% while its available monthly-close return is +32.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Regeneron Pharmaceuticals in Companies Radar
Explanations

Attention measures coverage volume, not quality

Acadia's 43.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Acadia in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Acadia's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 53/100 score.

Open Acadia in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon